SKF-77,434

SKF-77,434 is a drug that acts as a selective D1 receptor partial agonist, and has been researched for potential use in the treatment of Parkinson's disease. It is structurally related to the more well-known drug Fenoldopam, but has a different mechanism of action.

Pharmacology

SKF-77,434 is a D1 receptor partial agonist, meaning it binds to and activates the D1 receptor, but not to its full capacity. This is in contrast to a full agonist, which fully activates the receptor it binds to. The D1 receptor is one of five subtypes of dopamine receptors and is associated with cognitive and motor function.

Potential Therapeutic Uses

Research has suggested that SKF-77,434 may have potential use in the treatment of Parkinson's disease. Parkinson's disease is a neurodegenerative disorder characterized by the death of dopamine-producing cells in the brain. By acting as a D1 receptor partial agonist, SKF-77,434 could potentially help to alleviate some of the symptoms of Parkinson's disease by increasing dopamine activity in the brain.

Related Compounds

SKF-77,434 is structurally related to the drug Fenoldopam, a full D1 receptor agonist that is used to treat hypertension. However, the two drugs have different mechanisms of action, with Fenoldopam acting as a full agonist and SKF-77,434 acting as a partial agonist.

See Also

• Dopamine receptor D1
• Parkinson's disease
• Fenoldopam

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  SKF-77,434 Structure